NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
Conditions:   Borderline Resectable Pancreatic Carcinoma;   Locally Advanced Unresectable Pancreatic Adenocarcinoma;   Resectable Pancreatic Ductal Adenocarcinoma;   Stage 0 Pancreatic Cancer AJCC v8;   Stage I Pancreatic Cancer AJCC v8;   Stage IA Pancreatic Cancer AJCC v8;   Stage IB Pancreatic Cancer AJCC v8;   Stage III Pancreatic Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8
Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Drug: Leucovorin Calcium;   Drug: Losartan Potassium;   Drug: Oxaliplatin;   Radiation: Radiation Therapy;   Procedure: Resection
Sponsors:   OHSU Knight Cancer Institute;   Oregon Health and Science University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 30, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments